Recommendations

Most Recent

Sproutly Canada Inc.

Jimmy Mengel, The Crow's Nest (9/30/19) "SPR is in a good position and has already started expanding."

DURECT Corp.

Francois Brisebois, Laidlaw & Company (9/18/19) "DRRX's Phase 2a DUR-928 study in AH showed efficacy data and safety."

DURECT Corp.

Ed Arce, H.C. Wainwright & Co. (9/18/19) "DRRX's DUR-928 treatment led to improved prognosis in AH patients."

DURECT Corp.

Ed Arce, H.C. Wainwright & Co. (9/10/19) "DRRX earned a $10M milestone payment from Gilead."

DURECT Corp.

Brian Marckx, Zacks Small-Cap Research (8/19/19) "DRRX's licensing agreement with Gilead validates the SABER technology."

Biotechnology / Pharmaceuticals

DURECT Corp.

Francois Brisebois, Laidlaw & Company (9/18/19) "DRRX's Phase 2a DUR-928 study in AH showed efficacy data and safety."

DURECT Corp.

Ed Arce, H.C. Wainwright & Co. (9/18/19) "DRRX's DUR-928 treatment led to improved prognosis in AH patients."

DURECT Corp.

Ed Arce, H.C. Wainwright & Co. (9/10/19) "DRRX earned a $10M milestone payment from Gilead."

DURECT Corp.

Brian Marckx, Zacks Small-Cap Research (8/19/19) "DRRX's licensing agreement with Gilead validates the SABER technology."

DURECT Corp.

Francois Brisebois, Laidlaw & Company (8/2/19) "Recent developments at DRRX led to a substantial influx of capital."

Nutraceuticals

Avivagen Inc.

Clive Maund, CliveMaund.com (5/11/19) "This looks like an excellent point to buy back VIV."